Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
This is an open-label, randomized, multi-cohort, multi-center, phase Ib/II study to evaluate the safety and efficacy of Adebrelimab plus Irinotecan Liposome (II) with or without Famitinib in patients with extensive-stage small cell lung cancer (ES-SCLC) pre-treated with immune checkpoint inhibitor(s).
Extensive-stage Small-cell Lung Cancer
DRUG: Adebrelimab, Irinotecan Liposome (II)|DRUG: Adebrelimab, Irinotecan Liposome (II), Famitinib
6-month progression-free survival, Proportion of disease progression or death from randomization to 6 months of treatment., Up to 6 months
Safety, Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0., Up to 3 months after the last dose|Objective response rate, Objective response rate, determined according to RECIST v1.1 criteria., Up to 36 months|Progression-free survival, Progression Free Survival, determined according to RECIST v1.1 criteria., Up to 36 months|Overall survival, Overall survival is the time from randomization to death due to any reason or loss of follow-up., Up to 36 months|Disease control rate, Disease Control Rate, determined according to RECIST v1.1 criteria., Up to 36 months|Duration of response, Duration of Response, determined according to RECIST v1.1 criteria., Up to 36 months
This study is divided into two stages. Dose exploration will be conducted first, and after obtaining preliminary safety data it will be decided by investigator when to proceed with dose extension. The aim of this study is to observe and evaluate the safety and efficacy of Adebrelimab plus Irinotecan Liposome (II) with or without Famitinib.